- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Blackstone bankrolls supply chain player's deal spree with $275M | ||
| Di | ATAI adds MDMA biotech to growing list of psychedelic makers; Acadia adds $52.5M upfront pain buyout | ||
| Di | A small VC group expands its hunt for inspired biotech founders in need of seed cash | ||
| Di | Troy Wilson recruits AstraZeneca vet to steer Kura's late-stage pivot | ||
| Di | Agios just sold off the royalty rights for $255M, but Bristol Myers says Idhifa was a bust in PhIII. Now what? | ||
| Di | Ovid gets quick raise off PhII seizure results. Can the results hold up against GW? | ||
| Di | Covid-19 roundup: FDA chief Stephen Hahn walks back plasma comments, rejects internal 'deep state' opposition | ||
| Di | Exclusive: We asked for biopharma's opinion about the plasma EUA. And the industry offered a double-barreled response | ||
| Di | Takeda inks up to $500M collaboration with extra-cellular matrix biotech for NASH | ||
| Di | AbbVie options integrin-based compounds from Morphic, paving way for potential fibrosis treatments | ||
| Di | Tricida 'foreshadowed' its CRL - but shares still fall with fear of years-long delay | ||
| Di | Connect Biopharma snags $115 million in Series C to develop arsenal of immune modulators | ||
| Mo | Odonate announces 'positive' results but faces investor backlash; Aslan is once again recruiting clinical trial participants after months-long wait amid the pandemic | ||
| Mo | Vir enlists Covid-19 antibody rival for cancer, infectious disease discovery work | ||
| Mo | Onconova reports PhIII flop, putting high-risk MDS program on the chopping block | ||
| Mo | Bristol Myers hunkers down at the deals table, executing a new I/O play in biotech buyout | ||
| Mo | Tony Coles takes second neuroscience startup public as Yumanity reverse merges | ||
| Mo | Which big biopharma player should gamble $34B on a ripe rare-disease M&A target? An action-hungry top analyst fills in the blanks | ||
| Mo | Driving to the $278M mark on raises, a legendary R&D expert sets his sights on another pivotal goal line | ||
| Mo | Takeda gets a $2.2B deal for its OTC unit as debt-relief drive nears its end | ||
| Mo | Novartis' PD-(L)1 catch-up attempt stumbles in PhIII | ||
| Mo | Covid-19 roundup: Trump aides reportedly want vaccine before election; China began vaccine emergency use a month ago | ||
| So | Trump heralds a 'breakthrough' win in the R&D fight against Covid-19 - now comes the instant backlash as the FDA provides a controversial assist | ||
| Sa | The leaders in the race to develop a Covid-19 vaccine say they could have pivotal data in October - but Trump claims FDA is slowing recruitment | ||
| Fr | J&J adds yet another multiple myeloma regimen to the Darzalex label as Sanofi rival jumps in |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
